Have a personal or library account? Click to login
The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2 Cover

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

Open Access
|May 2021

Authors

Simone Ardern-Holmes

Sydney Children’s Hospital, Westmead, Sydney, Australia

Cassandra White

cassandra.white1@health.nsw.gov.au

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, Australia

Sarita Bahure

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, Australia

Simon So

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, Australia

Geoff McCowage

Sydney Children’s Hospital, Westmead, Sydney, Australia

Elizabeth Hovey

NHMRC CTC University of Sydney, Westmead, Sydney, Australia

Simon Troon

Hollywood Private Hospital, Perth, Western Australia, Australia

Paul De Souza

NHMRC CTC University of Sydney, Westmead, Sydney, Australia

John Simes

NHMRC CTC University of Sydney, Westmead, Sydney, Australia

Michael Slancar

Bond University, Queensland, Australia

Mark Dexter

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, Australia

Mark Wong

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, Sydney, Australia
DOI: https://doi.org/10.21307/ajon-2021-002 | Journal eISSN: 2208-6781 | Journal ISSN: 1032-335X
Language: English
Page range: 5 - 14
Published on: May 1, 2021
Published by: Australasian Neuroscience Nurses Association
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2021 Simone Ardern-Holmes, Cassandra White, Sarita Bahure, Simon So, Geoff McCowage, Elizabeth Hovey, Simon Troon, Paul De Souza, John Simes, Michael Slancar, Mark Dexter, Mark Wong, published by Australasian Neuroscience Nurses Association
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.